QNRX
Quoin Pharmaceuticals, Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-48/100
Last price
4.72
▲ 0.17 (3.62%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.16
Prev close
4.56
Day high
4.82
Day low
4.35
Volume
103.83K
Market cap
$22.68M
P/E (TTM)
—
52W range
3.25 – 41.80
Day trading desk
Gap from prior close
-8.67%
Prior close 4.55
VWAP
4.87
-3.06% from price
Relative volume
0.36×
Quiet session
Session range
30.05%
4.16 – 5.41
Position in range
45%
Mid range
ATR (14D)
0.56
11.97% of price
Prior day high
4.74
PDH
Prior day low
4.36
PDL
Bid / ask spread
—
Quote not published
Session volume
198.16K
Avg 548.93K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.28%
-5.2%
1M
-34.99%
-36.1%
3M
0.00%
-4.5%
6M
-25.32%
-43.5%
YTD
-67.29%
-81.5%
1Y
-34.44%
-50.9%
3Y
-96.75%
-179.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on QNRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
73.65K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 31, 26 | CULVERWELL ANTHONY JAMES Director |
BUY | 6.15K | $38.23K | Direct |
| Aug 31, 26 | CARTER DENISE P Chief Operating Officer |
BUY | 20.49K | $127.45K | Direct |
| Aug 31, 26 | MYERS MICHAEL Chief Executive Officer |
BUY | 20.49K | $127.45K | Direct |
| Aug 31, 26 | LAWLOR SALLY BRIDGET Chief Financial Officer |
BUY | 10.24K | $63.72K | Direct |
| Aug 27, 26 | LANGER DENNIS H Director |
STOCK | 34.53K | $177.85K | Direct |
| Aug 27, 26 | CULVERWELL ANTHONY JAMES Director |
STOCK | 31.35K | $161.46K | Direct |
| Oct 14, 25 | LANGER DENNIS H Director |
BUY | 15.15K | $212.89K | Direct |
| Dec 23, 24 | CARTER DENISE P Chief Operating Officer |
BUY | 555.56K | $250.00K | Direct |
| Dec 23, 24 | DUNN GORDON Chief Financial Officer |
BUY | 122.22K | $55.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CARTER DENISE P |
Chief Operating Officer | 37.71K | Purchase |
CULVERWELL ANTHONY JAMES |
Director | 40.36K | Purchase |
DUNN GORDON |
Chief Financial Officer | 151.08K | Purchase |
LANGER DENNIS H |
Director | 56.24K | Stock Award(Grant) |
LAWLOR SALLY BRIDGET |
Chief Financial Officer | 10.68K | Purchase |
MYERS MICHAEL |
Chief Executive Officer | 37.71K | Purchase |
Fundamentals
Market cap$22.68M
Enterprise value$703.38K
Revenue (TTM)—
Gross profit—
EBITDA$-19.05M
Net income$-18.67M
EPS (TTM)$-5.93
Free cash flow$-8.00M
Total cash$10.80M
Total debt$2.02M
Book value / share$8.76
Shares outstanding4.80M
Float1.93M
Short % of float6.31%
Dividend yield0.00%
Beta (5Y)1.75
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.48
PEG ratio—
Price / sales—
Price / book0.54
EV / revenue—
EV / EBITDA-0.04
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-575.73%
Return on assets-114.60%
Debt / equity51.46
Current ratio1.76
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $9.80M | $3.60M | $3.31M | $2.67M | +172.1% |
| Selling, general & admin | $6.49M | $5.93M | $6.07M | $6.58M | +9.5% |
| Total operating expense | $16.29M | $9.53M | $9.38M | $9.26M | +71.0% |
| Operating income | -$16.29M | -$9.53M | -$9.38M | -$9.26M | -71.0% |
| Net interest income | $482.08K | $558.49K | $694.61K | -$618.34K | -13.7% |
| Pre-tax income | -$15.80M | -$8.96M | -$8.69M | -$9.38M | -76.3% |
| Net income | -$15.80M | -$8.96M | -$8.69M | -$9.38M | -76.3% |
| Net income to common | -$15.80M | -$8.96M | -$8.69M | -$9.45M | -76.3% |
| Basic EPS | -14.80 | -66.85 | -337.47 | -1,638.23 | +77.9% |
| Diluted EPS | -14.80 | -66.85 | -337.47 | -1,638.23 | +77.9% |
| EBIT | -$16.29M | -$9.53M | -$9.38M | -$8.67M | -71.0% |
| EBITDA | -$16.19M | -$9.43M | -$9.27M | -$8.56M | -71.7% |
| Basic shares | 1.07M | 133.96K | 25.74K | 5.77K | +697.3% |
| Diluted shares | 1.07M | 133.96K | 25.74K | 5.77K | +697.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.82M | $3.62M | $2.40M | $2.86M | +5.4% |
| Cash & short-term investments | $18.75M | $14.06M | $10.69M | $12.85M | +33.4% |
| Total current assets | $20.01M | $14.93M | $11.29M | $13.37M | +34.0% |
| Goodwill & intangibles | $383.33K | $483.33K | $583.33K | $704.56K | -20.7% |
| Total assets | $20.39M | $15.71M | $12.17M | $14.46M | +29.8% |
| Total current liabilities | $5.55M | $4.18M | $3.58M | $3.53M | +32.7% |
| Total liabilities | $7.27M | $6.50M | $6.51M | $7.05M | +11.8% |
| Retained earnings | -$70.97M | -$55.17M | -$46.20M | -$37.52M | -28.6% |
| Shareholder equity | $13.12M | $9.20M | $5.66M | $7.41M | +42.5% |
| Working capital | $14.46M | $10.75M | $7.70M | $9.84M | +34.6% |
| Net tangible assets | $12.74M | $8.72M | $5.08M | $6.70M | +46.0% |
| Shares issued | 52.44M | 8.95M | 987.22K | 403.88K | +486.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.80M | -$8.96M | -$8.69M | -$9.38M | — | -76.3% |
| Depreciation & amortisation | $100.00K | $100.00K | $103.71K | $104.04K | — | 0.0% |
| Stock-based compensation | $1.15M | $1.26M | $1.09M | $764.01K | — | -8.9% |
| Change in working capital | $1.23M | -$2.14K | $95.45K | -$94.35K | — | +57,764.0% |
| Operating cash flow | -$13.54M | -$7.86M | -$7.86M | -$8.48M | — | -72.3% |
| Capital expenditure | — | — | — | -$250.00K | -$625.00K | — |
| Investing cash flow | -$4.28M | -$1.89M | $2.19M | -$10.15M | — | -126.5% |
| Financing cash flow | $18.01M | $10.97M | $5.22M | $14.01M | — | +64.2% |
| Free cash flow | -$13.54M | -$7.86M | -$7.86M | -$8.73M | — | -72.3% |
| End cash position | $3.82M | $3.62M | $2.40M | $2.86M | — | +5.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $3.63M | $3.43M | $3.10M | $2.28M | $2.05M | +5.6% |
| Selling, general & admin | $1.85M | $1.70M | $1.42M | $1.74M | $1.74M | +8.8% |
| Total operating expense | $5.47M | $5.13M | $4.52M | $4.02M | $3.79M | +6.7% |
| Operating income | -$5.47M | -$5.13M | -$4.52M | -$4.02M | -$3.79M | -6.7% |
| Net interest income | $100.95K | $146.78K | $171.70K | $62.27K | $103.25K | -31.2% |
| Pre-tax income | -$5.37M | -$5.00M | -$4.35M | -$3.95M | -$3.70M | -7.5% |
| Net income | -$5.37M | -$5.00M | -$4.35M | -$3.95M | -$3.70M | -7.5% |
| Net income to common | -$5.37M | -$5.00M | -$4.35M | -$3.95M | -$3.70M | -7.5% |
| Basic EPS | -1.90 | -1.77 | -1.74 | -6.71 | -6.28 | -7.3% |
| Diluted EPS | -1.90 | -1.77 | -1.74 | -6.71 | -6.28 | -7.3% |
| EBIT | -$5.47M | -$5.13M | -$4.52M | -$4.02M | -$3.79M | -6.7% |
| EBITDA | -$5.45M | -$5.11M | -$4.50M | -$3.99M | -$3.77M | -6.7% |
| Basic shares | 2.83M | 2.83M | 2.49M | 588.17K | 588.17K | +0.1% |
| Diluted shares | 2.83M | 2.83M | 2.49M | 588.17K | 588.17K | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.85M | $3.12M | $3.82M | $1.83M | $1.67M | +23.1% |
| Cash & short-term investments | $10.80M | $14.04M | $18.75M | $5.41M | $7.79M | -23.1% |
| Total current assets | $11.64M | $15.33M | $20.01M | $6.02M | $8.48M | -24.1% |
| Goodwill & intangibles | $333.33K | $358.33K | $383.33K | $408.33K | $433.33K | -7.0% |
| Total assets | $11.97M | $15.69M | $20.39M | $6.42M | $8.91M | -23.7% |
| Total current liabilities | $6.61M | $5.35M | $5.55M | $5.76M | $4.34M | +23.7% |
| Total liabilities | $8.04M | $6.92M | $7.27M | $7.64M | $6.36M | +16.1% |
| Retained earnings | -$81.34M | -$75.97M | -$70.97M | -$66.62M | -$62.67M | -7.1% |
| Shareholder equity | $3.93M | $8.77M | $13.12M | -$1.21M | $2.55M | -55.2% |
| Working capital | $5.02M | $9.99M | $14.46M | $250.78K | $4.14M | -49.7% |
| Net tangible assets | $3.60M | $8.41M | $12.74M | -$1.62M | $2.12M | -57.2% |
| Shares issued | 70.29M | 68.64M | 52.44M | 20.59M | 20.59M | +2.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$5.37M | -$5.00M | -$4.35M | -$3.95M | -$3.70M | -7.5% |
| Depreciation & amortisation | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | 0.0% |
| Stock-based compensation | $532.95K | $444.52K | $283.20K | $182.19K | $321.49K | +19.9% |
| Change in working capital | $1.72M | -$230.19K | -$917.81K | $1.51M | -$262.95K | +848.2% |
| Operating cash flow | -$3.14M | -$4.87M | -$5.04M | -$2.23M | -$3.69M | +35.4% |
| Investing cash flow | $4.02M | $4.12M | -$11.27M | $2.54M | $1.68M | -2.5% |
| Financing cash flow | -$151.95K | $55.98K | $18.29M | -$150.00K | -$150.00K | -371.4% |
| Free cash flow | -$3.14M | -$4.87M | -$5.04M | -$2.23M | -$3.69M | +35.4% |
| End cash position | $3.85M | $3.12M | $3.82M | $1.83M | $1.67M | +23.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.77 | -1.90 | -7.1% |
| Mar 2026 | -2.26 | -1.77 | +21.7% |
| Dec 2025 | -4.02 | -1.74 | +56.7% |
| Sep 2025 | -1.92 | -6.70 | -248.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.76 | 2 | $0 | 0.0% |
| Next quarter | -1.81 | 2 | $0 | 0.0% |
| Current year | -7.17 | 2 | $0 | 0.0% |
| Next year | -3.19 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$21.83
High target$35.00
Low target$12.00
Implied upside362.57%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders3.67%
Held by institutions27.75%
Institutions holding23
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.27
-10.48% from price
SMA 20
6.10
-22.59% from price
SMA 50
5.67
-16.81% from price
SMA 100
5.14
-8.14% from price
SMA 200
6.88
-31.38% from price
EMA 12
5.32
-11.23% from price
EMA 26
5.71
-17.34% from price
EMA 50
5.67
-16.80% from price
RSI (14)
35.2
Neutral
MACD (12,26,9)
-0.39
Hist -0.28
ATR (14)
0.56
11.97% of price
Realised vol 30D
105.2%
Annualised
Bollinger upper
8.14
20, 2σ
Bollinger lower
4.05
20, 2σ
50 / 200 cross
Death
5.67 vs 6.88
Trend bias
Below 200
-31.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-2.02
Less volatile than market
Correlation to SPY
-0.13
Largely independent
Realised vol 30D
105.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-85.4%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.56
11.97% of price
Beta (reported)
1.75
5Y monthly, from filing
Short interest
Shares short
126.29K
Prior 111.30K
Change vs prior
+13.5%
Shorts adding
% of float
6.31%
Normal
% of shares out
6.29%
Against total outstanding
Days to cover
0.1
Liquid
Float
1.93M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | Lake Street | INITIATED | — | Buy |
| May 4, 26 | LUCID CAPITAL MARKETS | INITIATED | — | Buy |
| Mar 15, 24 | Maxim Group | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateOct 23, 2019
Last split1:35
Split dateApr 9, 2025
SEC filings
Proxy Statements
DEF 14A · 2026-10-02
Proxy Statements
PRE 14A · 2026-09-22
Offering Registrations
S-3 · 2026-09-18
Additional Forms
D · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-08-28
Corporate Changes & Voting Matters
8-K · 2026-08-20
Periodic Financial Reports
10-Q · 2026-08-14
Proxy Statements
DEF 14A · 2026-07-16
Headlines
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
GlobeNewswire · 21h ago
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
GlobeNewswire · 15d ago
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
GlobeNewswire · 27d ago
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
GlobeNewswire · 29d ago
Quoin in line for priority review voucher if rare paediatric drug approved
Pharmaceutical Technology · 29d ago
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
GlobeNewswire · 29d ago
Sector Update: Healthcare Stocks Decline Friday Afternoon
MT Newswires · 40d ago
Top Midday Gainers
MT Newswires · 40d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.